Latest Ratios: P/E Ratio -0.1x · EV/EBITDA N/A · ROE N/A. (2018–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $5M | $33M | $29M | $118M | $321M | $678M | $1.1B | — | — |
| Enterprise Value | $4M | $32M | $-19493435 | $9M | $110M | $439M | $907M | — | — |
| P/E Ratio → | -0.08 | — | — | — | — | — | — | — | — |
| P/S Ratio | 2.57 | 16.70 | 2.61 | — | — | 2713.75 | 2668.76 | — | — |
| P/B Ratio | — | — | 2.01 | 1.66 | 1.78 | 3.22 | 5.45 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 16.24 | -1.77 | — | — | 1755.32 | 2114.16 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 91.6% | — | — | 100.0% | -4546.4% | -398.4% | -147.5% |
| Operating Margin | -2965.3% | -2965.3% | -672.2% | — | — | -38576.0% | -7016.1% | -543.6% | -265.7% |
| Net Profit Margin | -2980.3% | -2980.3% | -634.3% | — | — | -38160.8% | -8357.3% | -573.0% | -272.7% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | -164.3% | -98.4% | -53.8% | -45.3% | -46.6% | — | — |
| ROA | -179.9% | -179.9% | -81.1% | -71.5% | -43.9% | -38.2% | -28.2% | -229.4% | -174.2% |
| ROIC | — | — | — | — | — | — | — | — | — |
| ROCE | -398.2% | -398.2% | -114.5% | -88.2% | -49.5% | -43.1% | -30.8% | — | -379.4% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.06 | 0.03 | 0.02 | 0.03 | 0.00 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | -3.38 | -1.54 | -1.17 | -1.14 | -1.13 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | -31799.67 | -24.81 | -17.34 | -29.54 |
Net cash position: cash ($7M) exceeds total debt ($6M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.37 | 0.37 | 3.52 | 4.11 | 9.53 | 12.48 | 7.46 | 0.17 | 1.38 |
| Quick Ratio | 0.37 | 0.37 | 3.52 | 4.11 | 9.53 | 12.48 | 7.46 | 0.17 | 1.38 |
| Cash Ratio | 0.32 | 0.32 | 3.37 | 3.93 | 9.32 | 12.36 | 7.40 | 0.14 | 1.18 |
| Asset Turnover | — | 0.14 | 0.21 | — | — | 0.00 | 0.00 | 0.56 | 0.64 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $1M | $971467 | $955551 | $778545 | $691225 | $673272 | $673272 | $431772 |
Imminent liquidity exhaustion risk
As reported in recent financial statements, BCAB's price-to-sales ratio of 2.32 appears to be a function of minimal milestone-based revenue rather than commercial traction, suggesting that the market is pricing the equity primarily as a distressed option on the success of its clinical-stage ADC pipeline.
The lack of meaningful earnings or positive cash flow renders traditional P/E or EV/EBITDA multiples irrelevant for assessing intrinsic value. Investors should interpret the current valuation as a reflection of the high probability of further equity dilution, as the company lacks the commercial foundation to support its current market capitalization.
Based on the most recent quarterly data, BCAB's current ratio has collapsed to 0.15, which, according to regulatory filings, indicates a severe inability to meet short-term obligations and highlights a critical reliance on external financing to maintain ongoing clinical operations in the immediate term.
The rapid deterioration of the quick ratio from 4.49 in 2024Q1 to 0.15 in 2026Q1 underscores a structural liquidity crisis that leaves little room for operational error. This trend suggests that the company's ability to continue as a going concern is highly contingent on securing non-dilutive capital or a strategic partnership.
As indicated by the company's financial statements, the asset turnover ratio has remained consistently low at 0.13 in 2025Q4, confirming that the firm's capital base is not currently generating meaningful revenue, which is typical for a pre-commercial biotech firm focused on long-term R&D.
The low turnover ratio suggests that the company's investment in laboratory infrastructure and clinical trial assets has yet to translate into commercial output. This inefficiency is expected to persist until the company successfully transitions from a research-heavy model to a product-driven commercial entity.
According to institutional research standards, the use of P/S multiples for BCAB is fundamentally flawed because the reported $2.0 million TTM revenue is derived from sporadic licensing milestones rather than recurring product sales, which obscures the company's actual lack of sustainable commercial growth.
Analysts should instead focus on the 'Cash Runway Ratio' and the 'Burn Rate' to assess the company's viability, as these metrics provide a more accurate picture of the firm's survival prospects. Relying on revenue multiples in this context may lead to an overestimation of the company's current market position.
Includes 30+ ratios · 8 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BCAB stock.
BioAtla, Inc.'s current P/E ratio is -0.1x. This places it at the 50th percentile of its historical range.
Based on historical data, BioAtla, Inc. is trading at a P/E of -0.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
BioAtla, Inc. has 100.0% gross margin and -2965.3% operating margin.